Incyclix Bio is a next-generation cell cycle control company based in Durham, NC, specializing in precision treatments that target the abnormal proliferation responsible for various types of cancer.
With their lead compound, INX-315, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development, Incyclix Bio is at the forefront of understanding CDKs and their role in the cell cycle as attractive targets for ovarian, breast, and lung cancers.
Generated from the website